Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Generation of Real-world Evidence of Guselkumab in IBD Evaluating Effectiveness, Early Outcomes and Patient Relevant Aspects

NCT07102368 is registered in ClinicalTrials.gov with Janssen-Cilag G.m.b.H as lead sponsor.

NCT NCT07102368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Generation of Real-world Evidence of Guselkumab in IBD Evaluating Effectiveness, Early Outcomes and Patient Relevant Aspects
Lead sponsor
Janssen-Cilag G.m.b.H
Phase
Observational
Overall status
Recruiting
Start date
August 18, 2025
Completion date
January 15, 2029
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative, crohn's disease, inflammatory bowel disease